Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd Balance Sheet Health
Financial Health criteria checks 6/6
Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd has a total shareholder equity of CN¥2.4B and total debt of CN¥0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are CN¥2.9B and CN¥518.1M respectively. Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd's EBIT is CN¥77.2M making its interest coverage ratio -15.7. It has cash and short-term investments of CN¥1.2B.
Key information
0%
Debt to equity ratio
CN¥0
Debt
| Interest coverage ratio | -15.7x |
| Cash | CN¥1.20b |
| Equity | CN¥2.36b |
| Total liabilities | CN¥518.12m |
| Total assets | CN¥2.88b |
Recent financial health updates
We Think Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) Can Manage Its Debt With Ease
Mar 22
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) Seems To Use Debt Rather Sparingly
Dec 15Recent updates
What To Know Before Buying Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (HKG:1349) For Its Dividend
Apr 12We Think Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) Can Manage Its Debt With Ease
Mar 22Should You Be Adding Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) To Your Watchlist Today?
Mar 07Are Strong Financial Prospects The Force That Is Driving The Momentum In Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.'s HKG:1349) Stock?
Feb 20Could The Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (HKG:1349) Ownership Structure Tell Us Something Useful?
Feb 07Should Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) Be Disappointed With Their 38% Profit?
Jan 25Should You Rely On Shanghai Fudan-Zhangjiang Bio-Pharmaceutical's (HKG:1349) Earnings Growth?
Jan 12Would Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (HKG:1349) Be Valuable To Income Investors?
Dec 28Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) Seems To Use Debt Rather Sparingly
Dec 15Should You Be Adding Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) To Your Watchlist Today?
Dec 03Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.'s (HKG:1349) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Nov 21Financial Position Analysis
Short Term Liabilities: 1349's short term assets (CN¥1.9B) exceed its short term liabilities (CN¥505.0M).
Long Term Liabilities: 1349's short term assets (CN¥1.9B) exceed its long term liabilities (CN¥13.1M).
Debt to Equity History and Analysis
Debt Level: 1349 is debt free.
Reducing Debt: 1349 has no debt compared to 5 years ago when its debt to equity ratio was 15.7%.
Debt Coverage: 1349 has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: 1349 has no debt, therefore coverage of interest payments is not a concern.